EMA: Workshop outcome and recommendations: Current use and future needs of radiopharmaceuticals labelled with radionuclides produced in reactors and possible alternatives

In August 2008, the Dutch Authorities made the European Medicines Agency aware of potential shortages of radiopharmaceuticals due to the temporary shutdown of the High Flux Reactor (HFR) in Petten by the Nuclear Authority in the Netherlands. The HFR in Petten is responsible for the production of a large percentage of all radionuclides used as part of radiopharmaceutical medicinal products in Europe and about one third of the world supply.